Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Preferred Stock Liabilities (2020 - 2026)

Eledon Pharmaceuticals filings provide 1 years of Preferred Stock Liabilities readings, the most recent being $85.3 million for Q4 2013.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $85.3 million in Q4 2013 year-over-year; TTM through Dec 2013 was $85.3 million, a N/A change, with the full-year FY2013 number at $85.3 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $85.3 million in Q4 2013 for Eledon Pharmaceuticals.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $85.3 million in Q4 2013 to a low of $85.3 million in Q4 2013.